Literature DB >> 31732530

Cross-Reactivity to Kynureninase Tolerizes B Cells That Express the HIV-1 Broadly Neutralizing Antibody 2F5.

Joel Finney1, Guang Yang1, Masayuki Kuraoka1, Shengli Song1, Takuya Nojima1, Laurent Verkoczy2, Daisuke Kitamura3, Barton F Haynes1,4, Garnett Kelsoe5,4.   

Abstract

2F5 is an HIV-1 broadly neutralizing Ab that also binds the autoantigens kynureninase (KYNU) and anionic lipids. Generation of 2F5-like Abs is proscribed by immune tolerance, but it is unclear which autospecificity is responsible. We sampled the BCR repertoire of 2F5 knock-in mice before and after the first and second tolerance checkpoints. Nearly all small pre-B (precheckpoint) and 35-70% of anergic peripheral B cells (postcheckpoint) expressed the 2F5 BCR and maintained KYNU, lipid, and HIV-1 gp41 reactivity. In contrast, all postcheckpoint mature follicular (MF) B cells had undergone L chain editing that purged KYNU and gp41 binding but left lipid reactivity largely intact. We conclude that specificity for KYNU is the primary driver of tolerization of 2F5-expressing B cells. The MF and anergic B cell populations favored distinct collections of editor L chains; surprisingly, however, MF and anergic B cells also frequently expressed identical BCRs. These results imply that BCR autoreactivity is the primary determinant of whether a developing B cell enters the MF or anergic compartments, with a secondary role for stochastic factors that slightly mix the two pools. Our study provides mechanistic insights into how immunological tolerance impairs humoral responses to HIV-1 and supports activation of anergic B cells as a potential method for HIV-1 vaccination.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31732530      PMCID: PMC6904439          DOI: 10.4049/jimmunol.1900069

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  80 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  HIV vaccine design and the neutralizing antibody problem.

Authors:  Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Wayne C Koff; Peter D Kwong; John P Moore; Gary J Nabel; Joseph Sodroski; Ian A Wilson; Richard T Wyatt
Journal:  Nat Immunol       Date:  2004-03       Impact factor: 25.606

Review 3.  Molecular underpinning of B-cell anergy.

Authors:  Yuval Yarkoni; Andrew Getahun; John C Cambier
Journal:  Immunol Rev       Date:  2010-09       Impact factor: 12.988

4.  Antibody repertoire diversification through VH gene replacement in mice cloned from an IgA plasma cell.

Authors:  Rashmi Kumar; Martina P Bach; Federica Mainoldi; Mikako Maruya; Satoshi Kishigami; Hassan Jumaa; Teruhiko Wakayama; Osami Kanagawa; Sidonia Fagarasan; Stefano Casola
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-21       Impact factor: 11.205

5.  Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice.

Authors:  C C Goodnow; J Crosbie; S Adelstein; T B Lavoie; S J Smith-Gill; R A Brink; H Pritchard-Briscoe; J S Wotherspoon; R H Loblay; K Raphael
Journal:  Nature       Date:  1988-08-25       Impact factor: 49.962

6.  Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls.

Authors:  Laurent Verkoczy; Yao Chen; Hilary Bouton-Verville; Jinsong Zhang; Marilyn Diaz; Jennifer Hutchinson; Ying-Bin Ouyang; S Munir Alam; T Matt Holl; Kwan-Ki Hwang; Garnett Kelsoe; Barton F Haynes
Journal:  J Immunol       Date:  2011-09-09       Impact factor: 5.422

7.  The site and stage of anti-DNA B-cell deletion.

Authors:  C Chen; Z Nagy; M Z Radic; R R Hardy; D Huszar; S A Camper; M Weigert
Journal:  Nature       Date:  1995-01-19       Impact factor: 49.962

8.  BCR and Endosomal TLR Signals Synergize to Increase AID Expression and Establish Central B Cell Tolerance.

Authors:  Masayuki Kuraoka; Pilar B Snowden; Takuya Nojima; Laurent Verkoczy; Barton F Haynes; Daisuke Kitamura; Garnett Kelsoe
Journal:  Cell Rep       Date:  2017-02-14       Impact factor: 9.995

9.  ImageJ2: ImageJ for the next generation of scientific image data.

Authors:  Curtis T Rueden; Johannes Schindelin; Mark C Hiner; Barry E DeZonia; Alison E Walter; Ellen T Arena; Kevin W Eliceiri
Journal:  BMC Bioinformatics       Date:  2017-11-29       Impact factor: 3.169

10.  Identification and utilization of arbitrary correlations in models of recombination signal sequences.

Authors:  Lindsay G Cowell; Marco Davila; Thomas B Kepler; Garnett Kelsoe
Journal:  Genome Biol       Date:  2002-11-21       Impact factor: 13.583

View more
  6 in total

1.  Bioinformatics analyses of significant genes, related pathways, and candidate diagnostic biomarkers and molecular targets in SARS-CoV-2/COVID-19.

Authors:  Basavaraj Vastrad; Chanabasayya Vastrad; Anandkumar Tengli
Journal:  Gene Rep       Date:  2020-11-04

2.  Hide and seek: interplay between influenza viruses and B cells.

Authors:  Masayuki Kuraoka; Yu Adachi; Yoshimasa Takahashi
Journal:  Int Immunol       Date:  2020-09-08       Impact factor: 4.823

3.  Tracing Self-Reactive B Cells in Normal Mice.

Authors:  Takuya Nojima; Alexander E Reynolds; Daisuke Kitamura; Garnett Kelsoe; Masayuki Kuraoka
Journal:  J Immunol       Date:  2020-05-15       Impact factor: 5.422

4.  Continuous Culture of Mouse Primary B Lymphocytes by Forced Expression of Bach2.

Authors:  Joel Finney; Garnett Kelsoe
Journal:  J Immunol       Date:  2021-08-13       Impact factor: 5.426

Review 5.  Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies.

Authors:  Barton F Haynes; Kevin Wiehe; Persephone Borrrow; Kevin O Saunders; Bette Korber; Kshitij Wagh; Andrew J McMichael; Garnett Kelsoe; Beatrice H Hahn; Frederick Alt; George M Shaw
Journal:  Nat Rev Immunol       Date:  2022-08-12       Impact factor: 108.555

6.  Conditional antibody expression to avoid central B cell deletion in humanized HIV-1 vaccine mouse models.

Authors:  Ming Tian; Kelly McGovern; Hwei-Ling Cheng; Peyton Waddicor; Lisa Rieble; Mai Dao; Yiwei Chen; Michael T Kimble; Elizabeth Cantor; Nicole Manfredonia; Rachael Judson; Aimee Chapdelaine-Williams; Derek W Cain; Barton F Haynes; Frederick W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-24       Impact factor: 12.779

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.